AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18599019
Drug: Topical prednisolone
RxNorm normalized name: prednisolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prednisolone acetate 1% QID alone
Trial: 10699908
Drug: Weekly continuation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly continuation chemotherapy with rotating pairs of drugs (teniposide and cytarabine, vincristine and cyclophosphamide) with repeated reinduction with PVDA
Trial: 10699908
Drug: Weekly continuation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly continuation chemotherapy with rotating pairs of drugs (teniposide and cytarabine, vincristine and cyclophosphamide) without repeated reinduction with PVDA
Trial: 10699908
Drug: Allogeneic bone
RxNorm normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic bone marrow transplantation (BMT) instead of continued chemotherapy
Trial: 9347435
Drug: Mivacurium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium 0.3 mg/kg
Trial: 29173822
Drug: Clinical and
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical and home-based physical activity program (PAP) and simple lymphatic drainage (SLD), administered twice a week for six weeks.
Trial: 25493545
Drug: CC (Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC (Combination Condition)
Trial: 20229199
Drug: Pamidronate (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (30 mg disodium pamidronate, n=24)
Trial: 20229199
Drug: Pamidronate (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (30 mg disodium pamidronate)
Trial: 16490472
Drug: Nonselective NSAIDs
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonselective NSAIDs (diclofenac 50 mg BID or naproxen 500 mg BID)
Trial: 14988517
Drug: Extract of
RxNorm normalized name: Extract of tomato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extract of Perilla frutescens enriched for rosmarinic acid (200 mg)
Trial: 14988517
Drug: Extract of
RxNorm normalized name: Extract of tomato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extract of Perilla frutescens enriched for rosmarinic acid (50 mg)
Trial: 14988517
Drug: Extract of
RxNorm normalized name: Extract of tomato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extract of Perilla frutescens enriched for rosmarinic acid (200 mg and 50 mg combined)
Trial: 10751780
Drug: Local delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local delivery of heparin at 40- or 100-psi infusion pressure
Trial: 10751780
Drug: Local delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local delivery of heparin at 100 psi
Trial: 10751780
Drug: Local delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local delivery of heparin
Trial: 8453959
Drug: New inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New inhalation spacer device (Rondo) with salbutamol (Salbuvent)
Trial: 8453959
Drug: Salbutamol (Salbuvent)
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol (Salbuvent) with conventional metered dose actuator
Trial: 8453959
Drug: New inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New inhalation spacer device (Rondo)
Trial: 3518775
Drug: Theophylline (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (single dose, levels greater than 10 micrograms ml‐1)
Trial: 30035566
Drug: Doing everyday
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doing everyday solitary activities (e.g., reading, watching TV)
Trial: 29067598
Drug: Religious Cognitive
RxNorm normalized name: red delicious apple allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Religious Cognitive Behavioral Therapy (R-CBT)
Trial: 29067598
Drug: Conventional Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Cognitive Behavioral Therapy (C-CBT)
Trial: 25299079
Drug: Remifentanil preconditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil preconditioning (R3 group, 1.8 μg·kg(‐1)·min(‐1))
Trial: 23097240
Drug: Ketoconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (200 mg b.i.d. for 6 days)
Trial: 23097240
Drug: Safinamide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safinamide (100 mg single dose)
Trial: 20403374
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control (n=49)
Trial: 18936500
Drug: Sildenafil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (20 mg three times daily, titrated to 40 mg and 80 mg as tolerated)
Trial: 9821026
Drug: Out-patient treatment
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Out-patient treatment with low molecular weight heparin and oral anticoagulants, with daily attendance at the out-patient clinic.
Trial: 7644189
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for vasovagal syncope
Trial: 2504118
Drug: Mannitol cardioplegic
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol cardioplegic solution (59.8 mmol/L)
Trial: 1932652
Drug: Standard cardioplegic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cardioplegic solution
Trial: 2504118
Drug: Mannitol cardioplegic
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol cardioplegic solution
Trial: 197443
Drug: ACTH4-10 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTH4-10 (60 mg)
Trial: 30229989
Drug: Stable IS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable IS monotherapy 1 year after transplantation
Trial: 28178149
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of peripheral nerve block and general anesthesia (NB + GA)
Trial: 21771098
Drug: Hydrocortisone 1%
RxNorm normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 1% cream (HCT) applied twice daily for 4 weeks
Trial: 21771098
Drug: Hydrocortisone 1%
RxNorm normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 1% cream (HCT)
Trial: 21771098
Drug: Hydrocortisone 1%
RxNorm normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 1% cream (HCT) and Pimecrolimus 1% cream (PIM)
Trial: 20426883
Drug: Rimonabant (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant (20 mg)
Trial: 16816943
Drug: Lorazepam (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (0.02 mg/kg body weight)
Trial: 7919671
Drug: Low-dose hydrocortisone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hydrocortisone (10 mg/L) and heparin (500 U/L) added to peripheral intravenous fluid (feed A)
Trial: 7919671
Drug: Peripheral intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral intravenous fluid without heparin and hydrocortisone (feed B)
Trial: 2904523
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose solution (5.4 ml/h)
Trial: 26956188
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion (1.5 pmol·kg–1·min–1)
Trial: 21599819
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg bid with tenofovir/emtricitabine
Trial: 21599819
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg bid with optimized background therapy
Trial: 21599819
Drug: Efavirenz 600
RxNorm normalized name: efavirenz 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 600 mg at bedtime with tenofovir/emtricitabine
Trial: 21599819
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with optimized background therapy
Trial: 12230933
Drug: Caspofungin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin (50 mg/day)
Trial: 10684216
Drug: Emoxipin (2-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emoxipin (2-week monotherapy)
Trial: 218154
Drug: 3 percent
RxNorm normalized name: SALICYLIC ACID 3 g in 100 g TOPICAL GEL [Keralyt 3 PERCENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 percent vidarabine applied topically six times daily for 7 days
Trial: 7037982
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of Salmonella typhi strain Ty 21a oral vaccine (1‐8 X 10(9) live Ty 21a bacteria per dose)
Trial: 7037982
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three doses)
Trial: 22967171
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed in maxillary native bone (group A)
Trial: 22967171
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed in sinus-grafted sites (group B)
Trial: 22967171
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed in group B1 (simultaneous insertion)
Trial: 22967171
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed in group B2 (6 months after sinus lift)
Trial: 21774840
Drug: Quercetin-enriched cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin-enriched cereal bars (130 mg quercetin equivalents)
Trial: 21774840
Drug: Quercetin powder-filled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin powder-filled hard capsules (130 mg quercetin equivalents)
Trial: 21774840
Drug: Quercetin powder-filled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin powder-filled hard capsules
Trial: 21774840
Drug: Quercetin-enriched cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin-enriched cereal bars and quercetin powder-filled hard capsules
Trial: 17766567
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) group, 11-week duration
Trial: 1967516
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg vecuronium
Trial: 1967516
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg vecuronium
Trial: 28975304
Drug: Oral cephalexin
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cephalexin 500 mg and metronidazole 500 mg every 8 hours for 48 hours
Trial: 25799446
Drug: AH Plus®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AH Plus® sealer with immediate post space preparation
Trial: 25799446
Drug: AH Plus®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AH Plus® sealer with delayed post space preparation
Trial: 25799446
Drug: MTA Fillapex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTA Fillapex® sealer with immediate post space preparation
Trial: 25799446
Drug: MTA Fillapex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTA Fillapex® sealer with delayed post space preparation
Trial: 25799446
Drug: Positive control
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive control groups (no treatment)
Trial: 25799446
Drug: Negative control
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative control groups (no treatment)
Trial: 22906553
Drug: Ketamine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine at a psychotomimetic dose
Trial: 19240251
Drug: GHRH and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH and GHRP-2 infusion
Trial: 17976101
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy delivered to patients presenting with stable ventricular tachycardia (VT)
Trial: 17976101
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy delivered to patients with ischemic etiology
Trial: 17976101
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy delivered to patients with tiered therapy programmed ICDs
Trial: 17976101
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy delivered to patients using beta-blockers
Trial: 17976101
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to first appropriate therapy between first and second ICDs
Trial: 14679381
Drug: E+ (sucrose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E+ (sucrose, 100 g/l, 1672 kJ)
Trial: 11887021
Drug: Daily mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily mouthrinse with triclosan-zinc for 8 weeks
Trial: 11887021
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine spray for 2 weeks
Trial: 10438868
Drug: Intranasal spray
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal spray vaccination with 15 micrograms of HA and 2 micrograms of HLT
Trial: 10438868
Drug: Two nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two nasal spray vaccinations with 7.5 micrograms of HA with 1 microgram of HLT
Trial: 10438868
Drug: Single spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single spray vaccination with 15 micrograms of HA and 2 micrograms of HLT
Trial: 10438868
Drug: Parenteral virosomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral virosomal vaccine with 15 micrograms of HA without additional adjuvant
Trial: 8658281
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pefloxacin (Abaktal) and clindamycin
Trial: 2272604
Drug: Tolazamide (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolazamide (daily oral weight-adjusted)
Trial: 7450653
Drug: Retard tablet
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retard tablet (enteric-coated)
Trial: 7450653
Drug: Suppository (Euphyllin)
RxNorm normalized name: Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppository (Euphyllin)
Trial: 7450653
Drug: Intravenous preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous preparation
Trial: 31658037
Drug: Osteopathic manipulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulation treatment group (OMTG - n=23)
Trial: 25053388
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg veliparib (new formulation) under fasting conditions
Trial: 25053388
Drug: Four 10
RxNorm normalized name: Wal-Four 10 MG/ML Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four 10 mg current formulation capsules under fasting conditions
Trial: 25053388
Drug: Four 10
RxNorm normalized name: Wal-Four 10 MG/ML Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four 10 mg new formulation under fasting conditions
Trial: 20421537
Drug: Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel plus carboplatin (paclitaxel at 175 mg/m² IV over 3 hours plus carboplatin AUC = 6 IV over 30 minutes every 3 weeks)
Trial: 18826988
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 or 600 mg for 1 day; 300 + 75 or 150 mg daily for 7 days)
Trial: 2205135
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam 0.3 mg.kg‐1
Trial: 12472704
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.5 mg.kg(‐1)
Trial: 12472704
Drug: Rectal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rectal midazolam 0.5 mg.kg(‐1)
Trial: 12472704
Drug: Sublingual midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sublingual midazolam 0.3 mg.kg(‐1)
Trial: 1805295
Drug: Ethanol 1
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 1 g/kg body weight
Trial: 23934621
Drug: Ethanol 0.5
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.5 g/kg body weight
Trial: 27084954
Drug: Methotrexate 40
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 40 mg/m2/week
Trial: 25243574
Drug: T4 treatment
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: T4 treatment (N = 64)
Trial: 25243574
Drug: T4 treatment
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: T4 treatment (N = 64) with TSH ≥ 5 mIU/L
Trial: 25243574
Drug: T4 treatment
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: T4 treatment (N = 64) with TSH < 5 mIU/L
Trial: 25243574
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (N = 59)
Trial: 7485222
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg ibuprofen three times daily for 1 month
Trial: 7485222
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg piroxicam daily for 1 month
Trial: 7485222
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg sulindac twice daily for 1 month
Trial: 4023472
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A or B
Trial: 4023472
Drug: Treatment C
RxNorm normalized name: Acne Treatment Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C or D
Trial: 28745470
Drug: Taurine supplementation
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taurine supplementation (3 g of taurine with 400 mL low fat chocolate milk)
Trial: 28745470
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) with 400 mL low fat chocolate milk
Trial: 26425113
Drug: Usual monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Usual monthly group meetings (Control).
Trial: 21617573
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine (2 doses, 6 to 9 months apart)
Trial: 21617573
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine coadministered with MMR and varicella vaccines (2 doses of hepatitis A vaccine, 6 to 9 months apart)
Trial: 21617573
Drug: MMR and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR and varicella vaccines followed by 2 doses of hepatitis A vaccine (6 weeks later, 6 to 9 months apart)
Trial: 16865082
Drug: Levobupivacaine 0.5%
RxNorm normalized name: levobupivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.5% (group L)
Trial: 12699469
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (200 micro g daily)
Trial: 9603637
Drug: Norfloxacin 800
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norfloxacin 800 mg once-daily (Group A)
Trial: 9603637
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg twice-daily (Group B)
Trial: 3350994
Drug: Prednisone (PN)
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone (PN) 10-mg oral tablet
Trial: 3350994
Drug: Prednisolone (PL)
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone (PL) 10-mg oral tablet
Trial: 3350994
Drug: Intravenous Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Prednisone (IV PN) 10-mg